Of the 15 patients who relapsed or progressed with available BCMA and CD19 detection, 1 (7%) relapsed with BCMA-negative myeloma cells and 14 (93%) relapsed with BCMA-positive myeloma cells. Here, TNFRSF17 is linked to plasma cell myeloma.